Artis BioSolutions, a new CDMO, has been launched to aid the discovery, development and manufacture of genetic medicines.
The first move the company has made is to acquire Landmark Bio, a cell and gene therapy manufacturing company with specialist teams working on process development, advanced manufacturing technologies and translational research.
Though Landmark Bio will continue to operate as a distinct entity, its acquisition will aid Artis BioSolutions in offering its clients access to a wide range of advanced therapeutic manufacturing technologies designed to streamline and optimise the cell and gene therapy manufacturing process.
Genetic medicines: a key pharma opportunity
Complex genetic medicines are the fastest-growing therapeutic category, yet there is a shortage of high-quality service providers to support drug development in the space.
Contract Development and Manufacturing Organisations (CDMOs) that truly understand the development, scaling and regulatory hurdles of advanced therapies are often difficult to access, particularly for companies and researchers working in discovery and early-phase development.
To overcome these hurdles, industry leader-founded Landmark Bio has developed scientific and technical capabilities that aim to remove production bottlenecks, while also increasing speed to clinic.
“Landmark Bio was born from a bold vision shared by our founding partners – to remove barriers in the manufacturing of advanced therapies and accelerate the development of life-changing medicines," commented the company's CEO, Ran Zheng.
"Joining Artis BioSolutions will allow us to stay true to our mission as we scale our operations, allowing us to bring breakthrough therapies to more patients," he added.
“Advanced therapies will continue to be a driving force of innovation in the biopharma ecosystem, and we believe the industry is at an inflection point in advancing and developing the critical processes and the manufacturing of these therapies,” said Brian Neel, CEO of Artis BioSolutions.
“Landmark Bio has a proven track record of leading advanced therapies through clinical development, and we are excited to build on this foundation with the support of Oak HC/FT.”
“We see a tremendous opportunity to transform biomanufacturing at scale, and the Artis BioSolutions team has both the innovative drive and operational excellence to make it a reality. We are proud to support the team as they build this platform,” said Andy Smith, Partner at Oak HC/FT.